Vir Biotechnology Reminds Stockholders of 2021 Annual General Meeting Details
Vir Biotechnology (Nasdaq: VIR) will hold its 2021 Annual General Meeting of Stockholders on May 20, 2021, at 11:30 a.m. PT, in a virtual format only. Stockholders of record as of March 22, 2021, can attend by accessing the meeting center online. Stockholders are encouraged to vote and submit their proxy ahead of the meeting. Vir Biotechnology specializes in immunology, focusing on solutions for serious infectious diseases, with a pipeline targeting COVID-19, hepatitis B, influenza A, and HIV.
- Virtual meeting allows broader participation from stockholders.
- Focus on serious infectious diseases positions the company in a critical market.
- None.
SAN FRANCISCO, May 10, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on Thursday, May 20, 2021, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast.
Vir Biotechnology’s stockholders of record as of March 22, 2021 (the “Record Date”), can attend and vote at the Annual Meeting by accessing the meeting center at http://www.virtualshareholdermeeting.com/VIR2021 and entering the control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received. Instructions on how to connect to the Annual Meeting and participate via the Internet are also posted at http://www.virtualshareholdermeeting.com/VIR2021. Online access to the Annual Meeting will begin at 11:15 a.m. PT. Stockholders should allow ample time for the check-in procedures.
Whether or not stockholders plan to virtually attend the Annual Meeting, Vir Biotechnology urges them to vote and submit their proxy in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.
About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.
FAQ
When is Vir Biotechnology's 2021 Annual General Meeting?
How can I attend the Vir Biotechnology Annual Meeting?
What time is the Vir Biotechnology Annual Meeting scheduled for?
What is the record date for the Vir Biotechnology stockholders meeting?
What topics will be covered in the 2021 Vir Biotechnology Annual Meeting?
